camptothecin has been researched along with vorinostat in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, W; Dong, G; He, S; Huang, Y; Jiang, Y; Li, Z; Liu, N; Miao, Z; Sheng, C; Wang, Z; Yao, J; Zhang, W | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Chen, J; Gao, C; Jiang, Y; Li, D; Li, W; Liu, F; Yin, J; Yuan, Z; Zhang, Y | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Chatterjee, DR; Contractor, D; Jain, A; Kumar, D; Nagpure, M; Rana, P; Satpute, DP; Vaidya, GN; Venkatesh, A | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S | 1 |
| Bevins, RL; Zimmer, SG | 1 |
| Bruzzese, F; Budillon, A; Castelli, S; Desideri, A; Di Gennaro, E; Rocco, M | 1 |
| Chinnaiyan, P; Kahali, S; Sarcar, B | 1 |
| Brem, S; Chinnaiyan, P; Chowdhary, S; Kahali, S; Murtagh, R; Pan, E; Potthast, L; Prabhu, A; Rojiani, A; Sarcar, B; Tsai, YY; Yu, HM | 1 |
| Hetman, M; Vashishta, A | 1 |
| Hoffmann, OI; Ilmberger, C; Jauch, KW; Joka, M; Magosch, S; Mayer, B | 1 |
| Collier, AB; Gresh, RC; Kamara, DF; Kolb, EA; Sampson, VB; Vetter, NS | 1 |
| Fan, L; Jiang, T; Qiu, X; Yin, Y; Zhu, Q | 1 |
2 review(s) available for camptothecin and vorinostat
| Article | Year |
|---|---|
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
Topics: Animals; Cardiovascular Diseases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Neoplasms; Nervous System Diseases | 2021 |
1 trial(s) available for camptothecin and vorinostat
| Article | Year |
|---|---|
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxamic Acids; Insulin-Like Growth Factor Binding Protein 5; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Proteomics; Vorinostat | 2012 |
15 other study(ies) available for camptothecin and vorinostat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.
Topics: | 2015 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Topics: Acridines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Topoisomerase Inhibitors; U937 Cells | 2018 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspases; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Fibroblasts; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Liver Neoplasms; Membrane Potentials; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Skin; Tumor Cells, Cultured; Vorinostat | 2005 |
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Butyrates; Camptothecin; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin B; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteins; Survivin; Topoisomerase I Inhibitors; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Lung Neoplasms; Reactive Oxygen Species; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Vorinostat | 2009 |
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Proliferation; Comet Assay; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Hydroxamic Acids; Irinotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vorinostat | 2010 |
Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Cells, Cultured; Cerebral Cortex; Cisplatin; Dizocilpine Maleate; DNA Breaks, Double-Stranded; Etoposide; Genes, p53; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Hydroxamic Acids; Injections, Intraventricular; Neurons; Phosphorylation; Point Mutation; Protein Processing, Post-Translational; Pyridines; Rats; Rats, Sprague-Dawley; Tumor Suppressor Protein p53; Vorinostat | 2014 |
Impact of the spheroid model complexity on drug response.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cetuximab; Coculture Techniques; Everolimus; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Spheroids, Cellular; Stromal Cells; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Vorinostat | 2015 |
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; G1 Phase Cell Cycle Checkpoints; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sarcoma, Ewing; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53; Vorinostat | 2015 |
Targeting histones for degradation in cancer cells as a novel strategy in cancer treatment.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; Drug Therapy, Combination; Etoposide; Gamma Rays; Histone Deacetylase Inhibitors; Histones; Homeostasis; Humans; Hydroxamic Acids; Methyl Methanesulfonate; Mice; Valproic Acid; Vorinostat | 2019 |